Editorial
MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway
Abstract
Non-small cell lung cancer (NSCLC) is still challenging in terms of screening and treatment approaches (1). In Europe, Latin-America and US, NSCLC is among the most common diseases for both men and women (2).
